Canine Testicular Cancer

Canine testicular cancer encompasses a group of neoplasms arising from the various cell types within the testicle and represents one of the most common tumor categories in intact male dogs. The three primary tumor types are Sertoli cell tumors, seminomas, and interstitial (Leydig) cell tumors, which together account for the vast majority of testicular neoplasms in the canine population. These tumors occur with roughly equal frequency overall, though their relative proportions vary depending on whether the affected testicle is normally descended or retained within the abdomen or inguinal canal.

Testicular tumors are predominantly a disease of older intact male dogs, with the peak incidence occurring between seven and twelve years of age. The overall prevalence in intact male dogs has been reported to range from approximately three to twenty-seven percent depending on the study population and detection methods used. Many testicular tumors are incidental findings discovered during routine physical examinations or at the time of castration performed for other reasons, reflecting the often slow-growing and clinically silent nature of many of these neoplasms.

The biological behavior of testicular tumors varies considerably among the three major types. Interstitial cell tumors are almost universally benign and rarely cause clinical problems beyond the presence of a testicular mass. Seminomas are generally benign with a low metastatic rate of approximately five to ten percent. Sertoli cell tumors carry the highest malignant potential among the three types, with metastatic rates reported between ten and twenty percent, and they are also the type most likely to produce clinically significant hormonal effects.

A notable feature of canine testicular cancer is the strong association between cryptorchidism and tumor development. Dogs with undescended testicles have a significantly elevated risk of developing testicular tumors, particularly Sertoli cell tumors and seminomas, compared to dogs with normally descended testes. The retained testicle is exposed to the higher core body temperature of the abdomen or inguinal region, which is believed to promote neoplastic transformation of the germ cells and supporting cells within the gonad.

Sertoli cell tumors arise from the Sertoli cells, which are the supporting cells of the seminiferous tubules responsible for nurturing developing sperm cells. These tumors are of particular clinical significance because of their potential to produce estrogen and other hormones that can cause systemic effects. Sertoli cell tumors are the most common tumor type found in cryptorchid testes and tend to be more aggressive when they develop in retained testes compared to scrotal testes. They typically present as firm, lobulated masses within the testicular parenchyma and may cause notable enlargement of the affected testicle.

Seminomas originate from the germ cells of the seminiferous epithelium, which are the cells responsible for producing spermatozoa. These tumors tend to be soft, bulging masses that may be homogeneous or multinodular on cross-section. Seminomas are the second most common tumor type in cryptorchid testes and generally carry a favorable prognosis. While most seminomas are benign, a subset can exhibit malignant behavior with metastasis to regional lymph nodes and occasionally to distant sites including the lungs, liver, and spleen.

Interstitial cell tumors, also known as Leydig cell tumors, develop from the interstitial cells of Leydig located in the testicular stroma between the seminiferous tubules. These cells are responsible for producing testosterone and other androgens under the influence of luteinizing hormone. Interstitial cell tumors are the most common testicular tumor type in normally descended testes and are almost always benign. They are frequently small, well-circumscribed, soft to firm nodules that may be yellow to orange in color due to their lipid content. Multiple tumors within the same testicle or bilateral tumors are common.

Mixed testicular tumors containing elements of two or more tumor types occur in approximately fifteen to forty percent of cases and reflect the close anatomical proximity of the various cell populations within the testis. The biological behavior of mixed tumors is generally dictated by the most aggressive component present. Additionally, it is not uncommon for dogs to develop tumors in both testes simultaneously or sequentially, and the tumor types may differ between the two gonads. Rare testicular tumor types including teratomas, embryonal carcinomas, and gonadoblastomas have been reported in dogs but are uncommon.

Cryptorchidism is the single most significant risk factor for the development of canine testicular cancer, increasing the risk of tumor formation by approximately ten to fourteen times compared to dogs with normally descended testes. The risk is particularly elevated for Sertoli cell tumors and seminomas in retained testes, while interstitial cell tumors occur with similar frequency regardless of testicular position. Abdominal cryptorchid testes carry a higher tumor risk than inguinally retained testes, suggesting that the degree of temperature elevation plays a role in promoting neoplastic transformation.

Age is a major risk factor, as testicular tumors are predominantly a disease of middle-aged to older dogs. The cumulative exposure of testicular cells to hormonal stimulation, oxidative stress, and potential mutagenic agents over the course of a lifetime likely contributes to the age-related increase in tumor incidence. Dogs under five years of age rarely develop testicular tumors unless they have predisposing factors such as cryptorchidism.

Breed predispositions have been identified for testicular tumors, suggesting a genetic component to susceptibility. Boxers, German Shepherds, Afghan Hounds, Weimaraners, Shetland Sheepdogs, and Collies have been reported to have higher incidence rates. Since cryptorchidism itself has a hereditary basis and is more common in certain breeds, some of the breed-associated tumor risk is mediated through this mechanism. However, breed predispositions for testicular tumors in normally descended testes have also been reported, indicating that additional genetic factors beyond those related to testicular descent contribute to tumor susceptibility.

Environmental factors including exposure to certain chemicals and endocrine-disrupting compounds have been investigated as potential contributors to testicular cancer in dogs, paralleling research in human testicular cancer epidemiology. While definitive causal relationships have not been established in dogs, some studies have suggested associations between environmental contaminant exposure and increased testicular tumor risk. Hormonal imbalances and chronic testicular inflammation or trauma have also been proposed as contributing factors, though their roles remain incompletely characterized.

Many testicular tumors in dogs are clinically silent and are discovered incidentally during routine veterinary examinations. The most common physical finding is asymmetry of the testes, with one testicle being noticeably larger, firmer, or irregularly shaped compared to the contralateral gonad. Interestingly, the contralateral testicle may appear smaller than normal due to atrophy caused by hormonal feedback mechanisms, particularly in cases where the tumor is producing estrogen or other hormones that suppress gonadotropin secretion.

Feminization syndrome is a striking clinical presentation associated primarily with estrogen-secreting Sertoli cell tumors and, less commonly, with seminomas. The excess estrogen production leads to a constellation of clinical signs including bilateral symmetric alopecia, hyperpigmentation of the skin, gynecomastia (enlargement of the mammary glands), a pendulous prepuce, attraction of other male dogs, and squamous metaplasia of the prostate. The alopecia typically begins in the perineal and genital regions and may progress to involve the flanks, ventral abdomen, and trunk, creating a characteristic pattern that should prompt investigation of testicular abnormalities.

Bone marrow suppression is the most serious potential complication of estrogen-producing testicular tumors and represents a life-threatening emergency. Chronic estrogen excess leads to progressive myelosuppression, initially manifesting as nonregenerative anemia that may progress to pancytopenia affecting all blood cell lines. Thrombocytopenia can result in spontaneous hemorrhage, while leukopenia increases susceptibility to secondary infections. Estrogen-induced myelotoxicity can become irreversible if the hormonal source is not removed promptly, making early detection and treatment of estrogen-producing tumors critically important.

In cases of cryptorchid dogs with abdominal testicular tumors, clinical signs may include abdominal distension if the tumor reaches significant size, signs of abdominal discomfort, and in rare cases, acute abdominal crisis if the tumor undergoes torsion on its vascular pedicle. Metastatic disease, when it occurs, may produce signs related to the affected organs, including enlarged sublumbar or inguinal lymph nodes, respiratory signs from pulmonary metastases, or hepatomegaly from liver involvement.

The diagnostic evaluation of suspected testicular cancer in dogs begins with a thorough physical examination including careful palpation of both testes and the inguinal regions. In intact male dogs, both testes should be identified and evaluated for size, symmetry, consistency, and the presence of any masses or irregularities. If one or both testes cannot be palpated in the scrotum or inguinal area, cryptorchidism should be documented and abdominal imaging pursued to locate the retained gonad and assess for tumor development.

Ultrasonography is the primary imaging modality for evaluating testicular masses and can provide valuable information about tumor size, location, echogenicity, and vascular pattern. Most testicular tumors appear as hypoechoic or mixed-echogenicity masses within the testicular parenchyma, though the ultrasonographic appearance alone cannot reliably distinguish between the three major tumor types. Doppler ultrasonography can assess blood flow patterns within and around the mass, with increased vascularity suggesting more aggressive biological behavior.

Abdominal ultrasonography and thoracic radiography are recommended for staging purposes, particularly for tumors with higher metastatic potential such as Sertoli cell tumors and seminomas. The sublumbar lymph nodes are the primary regional drainage site for the testes and should be carefully evaluated for enlargement. Thoracic radiographs in three views allow assessment of the lungs for metastatic nodules, though pulmonary metastasis from testicular tumors is relatively uncommon.

A complete blood count is essential, particularly when an estrogen-producing tumor is suspected. Progressive nonregenerative anemia, thrombocytopenia, and leukopenia indicate estrogen-induced myelosuppression and represent a clinical emergency requiring prompt surgical intervention. Serum biochemistry panels may reveal elevated liver enzymes in cases with hepatic involvement. Hormonal assays measuring estrogen, testosterone, and inhibin levels can provide supportive diagnostic information but are not routinely performed. Definitive diagnosis and tumor typing require histopathological examination of the excised testicle, which remains the gold standard for classification, grading, and prognostication.

Surgical castration (bilateral orchiectomy) is the treatment of choice for canine testicular cancer and is curative in the vast majority of cases. Because concurrent tumors in the contralateral testicle are common, and because the remaining testicle is at risk for future tumor development, bilateral castration is strongly recommended over unilateral orchiectomy even when only one testicle appears clinically affected. The surgery is straightforward for scrotal testes and carries minimal risk in otherwise healthy patients.

For cryptorchid dogs with abdominal testicular tumors, surgery requires an abdominal approach (celiotomy or laparoscopy) to locate and remove the retained gonad. Abdominal tumors may have grown considerably before detection due to the lack of external visibility, and large tumors may require careful dissection to avoid intraoperative hemorrhage or damage to adjacent structures. Both the retained and the scrotal testicle should be removed during the same surgical procedure to eliminate any remaining neoplastic or preneoplastic tissue.

In cases complicated by estrogen-induced myelosuppression, preoperative stabilization is essential and may include blood transfusions, platelet-rich plasma administration, and broad-spectrum antibiotics to manage concurrent infections secondary to leukopenia. Surgical removal of the estrogen source is urgent in these patients, as continued estrogen exposure worsens the myelosuppression. However, the anesthetic and surgical risk is elevated in pancytopenic patients, requiring careful preoperative planning and close intraoperative monitoring. Recovery of bone marrow function following tumor removal is variable and depends on the duration and severity of myelosuppression prior to surgery.

Chemotherapy and radiation therapy are not commonly required for canine testicular tumors due to the generally favorable response to surgery alone. However, adjunctive chemotherapy may be considered for tumors with confirmed metastatic disease or those with histopathological features suggesting high malignant potential, such as lymphovascular invasion, high mitotic rate, or incomplete surgical margins. Cisplatin-based protocols have been used in cases of metastatic testicular cancer, drawing on experience from human oncology, though clinical data in dogs remain limited. Radiation therapy may be considered for localized residual or recurrent disease.

The prognosis for most canine testicular tumors is excellent following surgical castration. Interstitial cell tumors, being almost uniformly benign, carry a near-perfect prognosis with surgical cure rates approaching one hundred percent. Seminomas also carry a favorable prognosis, with the vast majority of cases cured by castration alone. Even in the small percentage of seminomas that have metastasized at the time of diagnosis, response to chemotherapy may extend survival significantly.

Sertoli cell tumors have a somewhat more guarded prognosis compared to the other two major types, primarily due to their higher metastatic potential and their association with estrogen-induced complications. Dogs with Sertoli cell tumors that have not metastasized and do not have significant myelosuppression typically have an excellent prognosis following castration. However, dogs presenting with advanced estrogen-induced pancytopenia face a more uncertain outcome, as bone marrow recovery is not guaranteed even after removal of the hormonal source.

Recovery from bone marrow suppression following surgical removal of an estrogen-producing tumor is a critical prognostic factor. Dogs with mild to moderate myelosuppression typically show improvement in blood cell counts within one to three weeks after surgery, with full recovery occurring over one to three months. Dogs with severe pancytopenia at the time of surgery may take longer to recover, and some may not recover adequate bone marrow function, particularly if the suppression has been prolonged. Serial complete blood counts should be monitored weekly during the recovery period.

Postoperative recovery from the surgical procedure itself is typically uneventful, with most dogs returning to normal activity within seven to fourteen days. The surgical site should be monitored for signs of swelling, discharge, or dehiscence, and an Elizabethan collar is recommended to prevent self-trauma. Long-term follow-up including periodic physical examinations, abdominal ultrasonography, and thoracic radiography is recommended for dogs with tumors that had metastatic potential, with monitoring intervals of three to six months for the first two years after surgery.

Elective castration (neutering) performed before the development of testicular tumors is the most effective preventive measure and completely eliminates the risk of testicular cancer. Since testicular tumors are a disease of intact male dogs, this simple and commonly performed surgical procedure provides absolute protection against all forms of testicular neoplasia. The decision regarding the optimal timing of neutering involves balancing the cancer prevention benefits against other health and developmental considerations.

For dogs known to be cryptorchid, early surgical correction or castration is strongly recommended. Because cryptorchid testes carry a significantly elevated cancer risk, retention of undescended testes is inadvisable from an oncological standpoint. Additionally, cryptorchidism is a heritable trait, and affected dogs should not be used for breeding. Veterinary guidelines generally recommend castration of cryptorchid dogs as soon as the condition is definitively identified, typically by six to twelve months of age when testicular descent should be complete.

The broader discussion around neutering timing has evolved in recent years as research has identified potential health trade-offs associated with early gonadectomy. Some studies have suggested associations between early neutering and increased risk of certain orthopedic conditions and other cancer types in specific breeds. These findings have led to more nuanced, breed-specific recommendations regarding the optimal age for neutering. Owners should discuss the timing of neutering with their veterinarian, taking into account the dog's breed, size, lifestyle, and individual risk factors.

For owners who choose to keep their male dogs intact for breeding purposes, personal preference, or other reasons, regular veterinary monitoring becomes essential. Intact male dogs should have their testes palpated during every routine veterinary visit, with increased vigilance in dogs over seven years of age. Any change in testicular size, symmetry, or consistency should prompt further diagnostic evaluation. Owner education about the signs of testicular tumors and the importance of regular examinations can facilitate early detection and treatment when tumors do develop.

Feminization syndrome, also known as hyperestrogenism or male feminizing syndrome, is one of the most clinically distinctive manifestations of canine testicular cancer and occurs most commonly in association with Sertoli cell tumors. This paraneoplastic condition results from the excessive production of estrogen by the tumor cells, leading to systemic hormonal effects that can be the presenting complaint prompting the owner to seek veterinary attention. Understanding the manifestations and consequences of feminization syndrome is essential for early recognition and timely intervention.

The dermatological changes associated with hyperestrogenism are often the most visually apparent and include bilateral symmetric alopecia that characteristically begins in the perineal and genital regions. The hair loss is noninflammatory and nonpruritic, distinguishing it from many other causes of alopecia. Affected skin may become hyperpigmented, thin, and may develop a ceruminous quality. The remaining hair coat may become dry, brittle, and dull. These changes develop gradually over weeks to months as estrogen levels progressively rise with tumor growth.

Reproductive and secondary sexual changes are prominent features of feminization syndrome. Gynecomastia, the development of mammary gland tissue, occurs as estrogen stimulates mammary ductal and stromal proliferation. The prepuce may become pendulous and edematous, and some affected dogs develop preputial dermatitis secondary to the altered tissue texture and increased moisture retention. Squamous metaplasia of the prostate gland occurs in response to estrogen stimulation and may predispose to prostatic cysts, abscesses, or secondary infections. Behavioral changes may include decreased libido, submissive behavior, and attractiveness to other male dogs.

The most dangerous consequence of sustained hyperestrogenism is myelotoxicity leading to bone marrow suppression. Estrogen exerts a biphasic effect on the bone marrow, with initial stimulation of erythropoiesis at lower concentrations followed by progressive suppression of all cell lines at higher or more prolonged exposures. The resulting pancytopenia produces a triad of anemia, thrombocytopenia, and leukopenia that can become life-threatening. Signs of myelosuppression include progressive weakness and pallor from anemia, spontaneous petechiation and hemorrhage from thrombocytopenia, and fever and secondary infections from neutropenia. This complication requires emergency intervention and carries a significant mortality risk.

For dog owners facing a diagnosis of testicular cancer, understanding the management pathway and expected outcomes can help alleviate anxiety and facilitate informed decision-making. In the majority of cases, the diagnosis of a testicular tumor is made during a routine examination, and the dog is otherwise healthy and asymptomatic. The discussion with the veterinarian will typically center on the recommendation for bilateral castration, preoperative staging workup, and the expected postoperative course.

Preoperative preparation is generally straightforward for uncomplicated cases involving scrotal tumors. Standard preoperative bloodwork including a complete blood count and serum biochemistry panel helps assess the dog's overall health and anesthetic risk, while also screening for evidence of hormonal effects such as myelosuppression. For older dogs or those with concurrent health conditions, additional preoperative assessments including electrocardiography, blood pressure measurement, and urinalysis may be recommended. The staging evaluation with abdominal ultrasound and thoracic radiographs helps determine whether the tumor has spread and informs the prognosis discussion.

Postoperative care following castration for testicular cancer is similar to routine castration recovery. Activity should be restricted for ten to fourteen days, and the incision site should be monitored for signs of complications. An Elizabethan collar prevents interference with the surgical site. Pain management with nonsteroidal anti-inflammatory drugs and additional analgesics as needed ensures the dog remains comfortable during healing. Most dogs return to their normal routines within one to two weeks of surgery.

The emotional impact of a cancer diagnosis in a beloved pet should not be underestimated, even when the prognosis is favorable. Owners may benefit from understanding that testicular cancer in dogs is one of the most treatable forms of cancer, with cure rates exceeding ninety percent for the most common tumor types when treated with surgery alone. Open communication with the veterinary team, including discussion of the histopathology results and long-term monitoring plan, helps owners feel confident in the care their dog is receiving. For the small percentage of cases involving metastatic disease or treatment-resistant tumors, consultation with a veterinary oncologist can provide access to advanced treatment options and specialized expertise.